Amendment: SEC Form S-1/A filed by IBO (Listing Market - NYSE Amex Network B F)
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future. Dear Impact Biomedical Inc. (IBO) Shareholders, We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your
HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our w
HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling Composition" developed within IBO's 3F™ technology platform. This is in addition to IBO's prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repellent, have the potential to reduce insect landings and bites experienced in an outdoor environment. The terms of U.S. Patents 11,985,973 and 11,246,310 will expire in February 2039 and April 2040, re
10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
3/A - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)